Trial Profile
An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2013
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 04 Dec 2013 New trial record